The pertussis therapeutic market is witnessing steady growth driven by rising incidences of whooping cough and increased vaccination efforts worldwide. Industry dynamics show evolving treatment protocols and introduction of novel therapies tailored for better efficacy. Pertussis therapeutic market trends reflect growing investments in research and a focus on expanding access in both developed and emerging economies.

Market Size and Overview

The Pertussis Therapeutic Market is estimated to be valued at USD 3.94 Bn in 2025 and is expected to reach USD 5.05 Bn by 2032, growing at a compound annual growth rate (CAGR) of 3.6% from 2025 to 2032.

This growth is supported by a rising patient base and advancements in therapeutic formulations targeting Bordetella pertussis infections. The Pertussis Therapeutic Market Report highlights steady market revenue growth, driven by sustained demand in pediatric and adult therapeutic segments.

Market Drivers
- Rising Incidence of Pertussis Worldwide: A key market driver for the pertussis therapeutic market is the resurgence of pertussis cases globally, particularly in regions with low immunization coverage. For instance, the CDC reported a 23% increase in whooping cough cases in the U.S. in 2024 compared to 2023, prompting urgent market opportunities for improved therapeutics and booster treatments. This surge has bolstered market growth strategies focused on innovation and expanding treatment access. This driver strongly influences the overall market size and market share dynamics across major geographies.

PEST Analysis
- Political: Government initiatives promoting immunization programs, such as increased funding by health ministries in Europe and Asia-Pacific in 2024, are positively impacting pertussis therapeutic market growth. Policy reforms facilitating faster drug approvals have accelerated treatment availability.
- Economic: The expanding healthcare expenditure in emerging markets, coupled with rising insurance coverage seen in 2025, supports enhanced patient affordability, driving business growth within the pertussis therapeutic industry size. Economic stability in key regions is encouraging market investments and expansions.
- Social: Growing public awareness campaigns about vaccine-preventable diseases have increased acceptance of therapeutic interventions. Shifts in population demography, such as the rise in elderly and immunocompromised individuals, are influencing demand and market forecast positively.
- Technological: Advances in biologics, combination therapies, and diagnostic tools are redefining market segments. The launch of novel mRNA-based pertussis therapeutic candidates in early 2025 exemplifies technological progress shaping industry trends and market revenue growth.

Promotion and Marketing Initiatives
Marketing initiatives in the pertussis therapeutic market increasingly focus on evidence-based awareness and stakeholder engagement. For example, in 2024, a major company launched a global digital campaign emphasizing the importance of booster therapeutics, resulting in a 15% increase in prescription rates in targeted markets within six months. Such promotion strategies enable better penetration in fragmented markets, bolstering market insights and creating sustainable market opportunities.

Key Players
- Tianjin CanSino Biotechnology
- ILiAD Biotechnologies
- GlaxoSmithKline (GSK)
- Sanofi
- AstraZeneca

Recent market growth strategies include:
- GSK’s expanded manufacturing capacity in 2025 to meet global demand surges, reported to increase their pertussis therapeutic market share by 3% in Europe.
- Sanofi’s launch of combination vaccines incorporating pertussis components in early 2024, enhancing their product portfolio with higher efficacy and broader patient reach.
- AstraZeneca’s strategic partnership with biotechnology firms to co-develop innovative therapies, announced in Q1 2025, targeting pediatric segments with promising clinical trial outcomes.


FAQs

Q1: Who are the dominant players in the pertussis therapeutic market?
Key market players include Tianjin CanSino Biotechnology, ILiAD Biotechnologies, GlaxoSmithKline, Sanofi, and AstraZeneca, who dominate through innovation, market expansion, and strategic partnerships.

Q2: What will be the size of the pertussis therapeutic market in the coming years?
The pertussis therapeutic market size is projected to grow from USD 3.94 billion in 2026 to USD 5.05 billion by 2032, expanding at a CAGR of 3.6%.

Q3: Which end-user industry has the largest growth opportunity?
The pediatric healthcare segment presents the largest growth opportunities owing to increased vaccination demand and rising whooping cough cases globally.

Q4: How will market development trends evolve over the next five years?
Market trends are expected to evolve through introduction of advanced biologics, combination therapies, and enhanced global vaccination campaigns, driving steady market size and business growth.

Q5: What is the nature of the competitive landscape and challenges in the pertussis therapeutic market?
The competitive landscape is robust, with major companies investing heavily in R&D and market expansion. Market challenges include regulatory hurdles, high R&D costs, and managing vaccine hesitancy in some regions.

Q6: What go-to-market strategies are commonly adopted in the pertussis therapeutic market?
Common strategies include strategic partnerships, innovative marketing campaigns, expanding manufacturing capabilities, and tailoring therapeutics to regional demand, all contributing to enhanced market opportunities and revenue growth.

‣ Get more insights on:  Pertussis Therapeutic Market

‣ Get this Report in Japanese Language:  百日咳治療薬市場

‣ Get this Report in Korean Language:   백일해치료시장

‣ Read More Related Articles: Clinical Trial Patient Recruitment Services: Rising Demand For New Drugs Driving Growth Of Recruitment Services

Author Bio:

Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc.